ClinicalTrials.Veeva
Menu

Find clinical trials for Kidney Disease in Warszawa, Mazowieckie

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases
Chronic Renal Insufficiency
Chronic Kidney Failure
IGA Glomerulonephritis
Renal Cell Carcinoma
Renal Insufficiency
Carcinoma

Kidney Disease trials near Warszawa, Mazowieckie, POL:

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney...

Enrolling
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Drug: Tolvaptan (OPC-41061)

Phase 3

Otsuka
Otsuka

Warszawa, Poland and 17 other locations

We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. W...

Active, not recruiting
Chronic Kidney Disease
Diabetes Mellitus, Type 2
Drug: Placebo (Semaglutide)
Drug: Semaglutide

Phase 3

Novo Nordisk
Novo Nordisk

Warszawa, Poland and 32 other locations

to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...

Enrolling
Chronic Kidney Disease With High Proteinuria
Drug: Dapagliflozin
Drug: Zibotentan/Dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Warszawa, Poland and 338 other locations

compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effec...

Enrolling
Chronic Kidney Disease
Drug: Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin
Drug: Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg

Phase 2

AstraZeneca
AstraZeneca

Warszawa, Poland and 116 other locations

This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2...

Enrolling
Chronic Kidney Disease
Obesity
Drug: Placebo
Drug: Cagrilintide

Phase 2

Novo Nordisk
Novo Nordisk

Warszawa, Poland and 114 other locations

The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the cl...

Enrolling
Chronic Kidney Disease
Cardiac Disease
Drug: Placebo
Drug: Ravulizumab

Phase 3

Alexion Pharmaceuticals
Alexion Pharmaceuticals

Warszawa, Poland and 186 other locations

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...

Enrolling
Chronic Kidney Disease
Proteinuria
Drug: Finerenone (Kerendia, BAY94-8862)

Phase 3

Bayer
Bayer

Warszawa, Poland and 144 other locations

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...

Enrolling
Chronic Kidney Disease
Proteinuria
Drug: Finerenone (Kerendia, BAY94-8862)
Drug: Placebo

Phase 3

Bayer
Bayer

Warszawa, Poland and 116 other locations

(for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.Parti...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Placebo (Ziltivekimab B)
Drug: Placebo (Ziltivekimab C)

Phase 3

Novo Nordisk
Novo Nordisk

Warszawa, Poland and 948 other locations

This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD)...

Active, not recruiting
End Stage Kidney Disease
Secondary Hyperparathyroidism
Drug: Open-Label Extension PLS240
Drug: PLS240

Phase 3

Pathalys Pharma

Warszawa, Mazowieckie, Poland and 67 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems